Mumbai, Oct. 25 -- Profit before tax (PBT) stood at Rs 1,835 crore in Q2 FY26, down 4.26% year on year.

EBITDA for the quarter stood at Rs 2,351 crore, up 3% as against Rs 2 ,280 crore posted in Q2 FY25.

In its global generics business, North America contributed Rs 3,240.8 crore in revenue, a 13.07% year-on-year decline. Revenue from Europe surged 138.50% to Rs 1,376.2 crore, The India business generated revenue of Rs 1,578 crore, registering an 12.94% YoY.

Revenue from pharmaceutical services and active ingredients (PSAI) came in at Rs 944.99 crore, a 12.40% YoY increase.

In Q2 FY26, the company advanced its global presence through key acquisitions, product launches, and partnerships. It acquired the STUGERON portfolio across 18 APAC...